LTRN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process...

Stats
今日成交量	189 247
平均成交量	331 506
市值	66.17M
EPS	$0 ( 2024-03-18 )
下一个收益日期	( $-0.400 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.18
ATR14	$0.0660 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-27	Fletcher Aaron G.l.	Sell	34 731	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	51 608	Common Stock
2024-02-29	Fletcher Aaron G.l.	Sell	13 686	Common Stock
2024-02-27	Fletcher Aaron G.l.	Sell	10 620	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	15 780	Common Stock

INSIDER POWER
-63.11
Last 98 transactions
Buy: 4 152 509 \| Sell: 1 662 260

音量相关性

長: -0.13 (neutral)

短: -0.94 (very strong negative)

Signal:(53.547) Neutral

Lantern Pharma Inc. 相关性

10 最正相关
MEUSW	0.931
CELH	0.899
CSLMU	0.895
SOUN	0.895
SUPN	0.893
NOTV	0.887
BYSI	0.884
XRTX	0.884
FSII	0.879
DGLY	0.878

10 最负相关
IOAC	-0.845
METX	-0.834
XEL	-0.83
ASRVP	-0.829
SABR	-0.826
WAVS	-0.825
CLMT	-0.81
BOWX	-0.802

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lantern Pharma Inc. 相关性 - 货币/商品

0.77
( moderate )

0.54
( weak )

0.00
( neutral )

0.76
( moderate )

0.37
( neutral )

-0.80
( strong negative )

Lantern Pharma Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2023
营收:	$0
毛利润:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2022
营收:	$0
毛利润:	$-154 681 (0.00 %)
EPS:	$-1.300

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.105

Financial Reports:

No articles found.

Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

实时更新： Lantern Pharma Inc. [LTRN]

Upcoming Earnings Alert